Controlled HSV-2 Infection for Lifelong Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively prevent Herpes Simplex 2 (HSV-2) infections in individuals and newborns during birth, leading to recurring painful outbreaks and potential neonatal mortality.
Innovation Solution
The Herpes 2 Antibody System intentionally infects individuals with a controlled and regulated dose of HSV-2, generating antibodies to prevent future infections, while ensuring the host is screened for other pathogens to avoid transmission, and utilizing a medical clinic with licensed professionals for the process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current Herpes medication is used, then outbreaks can be controlled to some extent, but the medication does not always work and requires continuous use without providing lifelong protection
Solution Approach 1:
The patent applies preliminary action by intentionally infecting the host with HSV-2 under controlled conditions before natural exposure occurs. This pre-infection triggers the immune system to produce antibodies in advance, providing lifelong protection without requiring continuous medication. The controlled infection is performed once in a clinical setting, eliminating the need for ongoing drug treatment.
2Reliability
If intentional infection is performed to generate antibodies, then lifelong immunity is achieved, but the process is complicated, time-consuming, and expensive
Solution Approach 1:
The patent applies self-service by allowing the host's own immune system to generate the necessary antibodies through controlled exposure to HSV-2. Rather than requiring complex external antibody production facilities or sophisticated medical interventions, the host's body naturally produces the protective antibodies when exposed to the virus under controlled conditions. This leverages the body's inherent immune response capabilities.
3Reliability
If controlled infection is used to generate antibodies, then protection from HSV-2 is achieved, but there is risk of transmitting other pathogens if host screening is inadequate
Solution Approach 1:
The patent applies intermediary by introducing a controlled infection process that acts as a mediator between the host and HSV-2 exposure. The controlled environment and screening protocols serve as intermediary safeguards, allowing the beneficial antibody generation while filtering out the risk of pathogen transmission. The controlled infection is performed through specific clinical procedures that minimize contamination risks.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This system generates lifelong immunity against HSV-2, preventing painful outbreaks and neonatal infections, thereby benefiting humanity and reducing emotional and physical suffering.
Implementation Method 1
My system will also generate antibodies for HSV-2 (HERPES 2)
Data Source
AI summary
The HERPES 2 ANTIBODY SYSTEM prevents people from getting HERPES 2. It prevents people from getting HERPES SIMPLEX 2 VIRUS (HSV-2) (HERPES 2) on their genitals, mouth, anus, hands, eyes and face. And it prevents a baby from getting infected with HERPES 2 during birth.